Cancer diagnostics company Pacific Edge (NZE:PEB, ASX:PEB) said tests processed at its laboratories in the three months to the end of September were 2% lower than the prior quarter at 7,045, according to a Wednesday filing with the Australian and New Zealand bourses.
Asia Pacific volumes rose 6.2% to 1,363 tests from 1,283 in fiscal Q1, reflecting increased volumes in New Zealand and small growth from Australia and Asian distributors, the filing stated.
Group test volumes for the half year fell 22% to 14,233 from 18,240 in the first half of fiscal 2024, according to the filing.
Pacific Edge shares fell past 4% in recent Wednesday trade in New Zealand.
Price (AUD): $0.16, Change: $-0.0070, Percent Change: -4.32%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。